Author: admin

Thyroid Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, Companies by DelveInsight

DelveInsight’s, “Thyroid Cancer Pipeline Insight” report provides comprehensive insights about 50+ companies and 51+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Thyroid Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Thyroid Cancer Pipeline Report to explore emerging therapies, key Thyroid Cancer Companies, and future Thyroid Cancer treatment landscapes @ Thyroid Cancer Pipeline Outlook Report

Key Takeaways from the Thyroid Cancer Pipeline Report

  • In February 2025:- Bayer:- This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.
  • In February 2025:- Turning Point Therapeutics, Inc.:- Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
  • In February 2025:- Sanofi:- The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with vandetanib
  • In February 2025:- Loxo Oncology Inc.:- The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
  • In February 2025:- Eli Lilly and Company;- A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation.
  • DelveInsight’s Thyroid Cancer pipeline report depicts a robust space with 50+ active players working to develop 51+ pipeline therapies for Thyroid Cancer treatment.
  • The leading Thyroid Cancer Companies such as AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
  • Promising Thyroid Cancer Therapies such as Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.

Discover how the Thyroid Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Thyroid Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Thyroid Cancer Clinical Trials and Studies

Thyroid Cancer Emerging Drugs

  • rhTSH: Suzhou Zelgen Biopharmaceuticals

Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without the requirement for THST withdrawal and the resultant metabolic disturbance, and without the drawbacks associated with the use of bovine TSH. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with thyroid cancer.

  • Nivolumab: Bristol-Myers Squibb

Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with thyroid cancer.

  • RX208: Suzhou NeuPharma

RX208 is a potential “best-in-class” BRAF V600E inhibitor with a proprietary novel chemical structure that is different from other marketed BRAF inhibitors. It exhibited high bioavailability and excellent anti-tumor efficacy in preclinical studies. Early clinical data demonstrated preliminary efficacy and good safety and tolerability in patients with cancer, warranting further clinical development. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with thyroid cancer.

  • AIC100: AffyImmune Therapeutics

AffyImmune’s lead product, AIC100, is an affinity-tuned, ICAM-1 targeted, third generation CAR T cell therapy. AIC100’s CAR has an affinity to ICAM-1 similar to the affinity between naturally-occurring T cells and their targets, which is much lower than most CARs used to date and reduces on-target off-tumor toxicities. AIC100 also expresses SSTR2 for real-time monitoring of CAR T cell distribution and activity. Preclinical studies demonstrate that AIC100 induces robust and enduring tumor eradication without toxicity-related relapse or fatality in various solid tumor models. Studies also suggest the potential for combination with anti-PD-1 therapies. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Thyroid Cancer.

The Thyroid Cancer pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Thyroid Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Thyroid Cancer Treatment.
  • Thyroid Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Thyroid Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Thyroid Cancer market.

Get a detailed analysis of the latest innovations in the Thyroid Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Thyroid Cancer Unmet Needs

Thyroid Cancer Companies

AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.

Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Thyroid Cancer Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

Download DelveInsight’s latest report to gain strategic insights into upcoming Thyroid Cancer Therapies and key Thyroid Cancer Developments @ Thyroid Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Thyroid Cancer Pipeline Report

  • Coverage- Global
  • Thyroid Cancer Companies- AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
  • Thyroid Cancer Therapies- Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
  • Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Thyroid Cancer drug development? Find out in DelveInsight’s exclusive Thyroid Cancer Pipeline Report—access it now! @ Thyroid Cancer Emerging Drugs and Major Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Thyroid Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Thyroid Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. rhTSH: Suzhou Zelgen Biopharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Nivolumab: Bristol-Myers Squibb
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AIC100:Affyimmune Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Thyroid Cancer Key Companies
  21. Thyroid Cancer Key Products
  22. Thyroid Cancer- Unmet Needs
  23. Thyroid Cancer- Market Drivers and Barriers
  24. Thyroid Cancer- Future Perspectives and Conclusion
  25. Thyroid Cancer Analyst Views
  26. Thyroid Cancer Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/car-t-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Thyroid Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, Companies by DelveInsight

Automotive Shredded Residue (ASR) Market Size, Growth Rate, Industry opportunities, Latest Study Reveal for the forecast

“Browse 158 market data Tables and 41 Figures spread through 252 Pages and in-depth TOC on “Automotive Shredded Residue (ASR) Market””
The Automotive Shredded Residue (ASR) market is driven by rising vehicle recycling rates and sustainability efforts. Advances in material recovery and stringent environmental regulations are shaping market growth. Innovations in sorting technologies and growing circular economy initiatives will further boost demand for ASR recycling solutions.

The Automotive shredded residue (ASR) market is projected to reach USD 1.6 billion by 2028, at a CAGR of 6.6% from USD 1.1 billion in 2023. The automotive shredded residue market growth is driven by factors such as regulatory pressure from government and environmental agencies, continuous technological advancement in post shredding technology, rising resource scarcity, and increasing demand for recycled materials.

The growth of the automotive shredded residue (ASR) market is primarily driven by escalating resource scarcity and a growing need for recycled materials. Regulatory pressures from government and environmental agencies, coupled with ongoing technological innovations in post-shredder technology, further contribute to its expansion.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162123480

“Plastics by composition is projected to be the largest, in terms of value, during the forecast period.”

Various industries, particularly packaging, automotive, and consumer goods, are witnessing a growing demand for recycled plastics as companies seek sustainable materials that align with environmental objectives. Governments across many countries are implementing regulations and offering incentives to encourage recycling and the utilization of recycled materials. These regulatory measures can stimulate investments in post-shredder technologies for plastics. The concept of a circular economy, which promotes the reuse and recycling of materials rather than disposal, is gaining traction. This momentum encourages the development of technologies that efficiently process and recycle plastics into new products. Heightened public awareness of plastic pollution in oceans and ecosystems has led to calls for more effective recycling and waste management solutions, prompting investments in technologies capable of handling post-shredder plastics with greater efficiency.

“North America is expected to be the fastest growing market for post shredder technology during the forecast period, in terms of value.”

The adoption of post shredder technology in the North American region is attributed to several driving factors. North America, especially the United States and Canada, is characterized by a robust industrial and manufacturing sector that generates substantial volumes of industrial and post-consumer waste, creating a demand for efficient processing and recycling solutions like post shredder technology. The region also navigates a complex regulatory landscape woven with federal, state, and provincial regulations governing waste management and recycling, propelling the necessity for advanced technologies to meet regulatory standards and optimize recycling processes. Furthermore, North America showcases a growing environmental consciousness among consumers and businesses, fueling a heightened demand for recycling and waste reduction solutions and thereby bolstering the automotive shredder residue (ASR) market. Additionally, North America has a history of significant investments in research and development, fostering the advancement and adoption of state-of-the-art recycling technologies and contributing to the expansion of the post-shredder technology market.

The region’s wealth of resources, including valuable metals and plastics crucial for recycling processes, acts as an incentive for investments in recycling technologies. Importantly, key industries within North America, such as automotive, manufacturing, and packaging, demonstrate a robust appetite for recycled materials, serving as a catalyst for the development of technologies that efficiently handle post-shredder materials.

Automotive Shredded Residue (ASR) Companies

The key players in this market are Tomra Systems ASA (Norway), Gallo (Belgium), Sims Limited (Australia), MBA Polymers Inc.(US), and Binder+Co. (Austria), PLANIC (Japan), Axion Ltd.(UK), SRW Metal float GmbH (Germany), Machinex Industries, Inc. (Canada), Wendt Corporation (US), CP Manufacturing Inc. (US), BT-Wolfgang Binder GmbH (Austria), Agilyx (US), Steinert (Germany), etc. These companies demonstrate a robust presence in their local markets and are actively exploring opportunities for geographical diversification to expand their operations. Their strategic emphasis lies in expanding their market footprint by introducing new products and persuing different avenues for growth.

Tomra Systems ASA

Established in 1972, Tomra Systems ASA initially focused on designing, manufacturing, and selling reverse vending machines (RVMs) for the automated collection of used beverage containers. Today, the company has evolved into a technology-driven company that plays a crucial role in advancing the circular economy. They offer cutting-edge solutions in collection and sorting systems, as well as food processing, incorporating sensor-based sorting and grading technology. The company is headquartered in Asker Municipality in Norway.

The company operates through three primary business segments: Collection, Recycling, and Food. It offers a diverse range of solutions in areas such as Food, Mining, Reverse vending, and Recycling.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=162123480

In total, Tomra has installed around 105,000 systems across more than 100 markets globally. The Tomra Group has a global workforce of 5,000 employees and is a publicly-traded company. TOMRA has a widespread presence, spanning all continents and offering its services in regions like Asia-Pacific, Europe, The Americas, and beyond.

Gallo

Galloo is a prominent European recycling company specializing in ferrous and non-ferrous metals. The company utilizes post-shredder technology, which involves additional processing of materials after shredding. Galloo company boasts a robust plastics recycling production capacity of 90,000 tons per year. Galloo Plastics, a specialized division within the Galloo Group, specializes in plastic processing. Through strategic investments, Galloo Recycling Group boasts an extensive network with over 40 divisions spread across Belgium, France, and The Netherlands.

Sims Limited

Established in 1917, Sims Limited stands as a prominent global figure in metal recycling, as well as offering circular solutions for technology and emerging as a leader in renewable energy. Sims Limited also engages in the processing of ferrous metals for subsequent resale, employing a range of techniques such as sorting, shredding, cutting, torching, baling and breaking. The company’s focal point on employing advanced machine sorting methods like Eddy Current Systems for industrial, consumer and vehicle scrap metal enabling it to achieve elevated rates of metal recovery. Operating under a subsidiary of Sims Limited, Sims Resource Renewal shares a collective mission to contribute to a waste free world and the conservation of our planet. The company’s objective entails utilizing over 1 million tons of Automotive Shredder Residue (ASR) annually by 2030, transforming this material into new innovative products.With a workforce of 4,000 individuals, Sims Limited has over 260 facilities spanning across 15 countries. The company possesses processing facilities across the Americas, EMEA and APAC regions.

MBA Polymers Inc.

In1997, MBA Polymers Inc. was established in California. The company started operating as a modest production facility in Richmond, Virginia. Through years of unwavering commitment and strategic investments, MBA Polymers Inc. emerged as a global frontrunner in recycling plastics from end-of-lfe durable goods including computers, electronic appliances and automobiles. MBA Polymers Inc. serves as both a research and development center and a hub for managing licenses and intellectual property. The company has obtained over 40 patents worldwidefor its advancements.

Since 2001, MBA Polymers Inc. has established five clean-tech facilities in Germany, Austria, China,The UK and the US. These facilities have an impressive annual capacity of over 150,000 tons, which makes them the most advanced plastic recycling facilities in the world.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=162123480

Binder+Co.

Binder+Co. is a global leader in providing sorting and processing solutions for industries such as recycling, mining, and raw materials. With a strong focus on sustainability and resource efficiency, the company designs, manufactures, and supplies advanced equipment and technologies that contribute to the effective sorting and processing of materials, promoting a circular economy and environmental responsibility. The company operates in the key business segments of packaging technology, processing technology and environmental technology. The company provides its sorting equipment through the environmental technology segment. The company specializes in the development and production of cutting-edge sorting equipment and technologies. These solutions are designed to efficiently separate and classify materials based on their properties like shape,size, colouer and composition.

Binder+Co. has a strong global presence and serves customers in various regions worldwide. The company is headquartered in Gleisdorf (Austria). In addition to its central location in Austria, the company has well established international footprint with subsidiaries and sales offices in key regions including Europe, Asia, North America, South America and Africa.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/automotive-shredded-residue-asr-market-162123480.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Automotive Shredded Residue (ASR) Market Size, Growth Rate, Industry opportunities, Latest Study Reveal for the forecast

Surging Demand for Payroll Processing Providers Amid Growing Tax Compliance Challenges

“payroll processing providers in usa”
As businesses face increasing payroll challenges, the demand for expert payroll processing providers rises. Cloud-based platforms, automation, and integrated tax filing services help businesses streamline operations, enhance efficiency, and ensure compliance with evolving tax laws. Small and medium-sized businesses benefit from outsourcing payroll tasks, allowing them to focus on growth. IBN Technologies offers innovative solutions to simplify payroll management and improve accuracy.

Miami, Florida, February 19, 2025 – As businesses across the United States face increasing challenges in managing payroll, including the complexities of staying compliant with ever-changing tax regulations and avoiding costly errors, the demand for payroll processing providers continues to rise. Companies of all sizes are seeking expert assistance to streamline payroll operations, ensure timely tax filings, and mitigate the risk of compliance issues. Outsourcing payroll has become a necessity for businesses looking to stay efficient and reduce costly mistakes.

Streamline operations—integrate payroll and tax filing services today! Click here

One of the most significant trends in payroll processing is the widespread adoption of cloud-based platforms. These solutions offer flexibility and efficiency, allowing businesses to manage payroll from virtually anywhere. With many companies operating remote teams or managing multiple locations, cloud-based payroll systems are invaluable. These platforms also integrate seamlessly with accounting software, ensuring accurate financial management and minimizing the risk of errors. By moving payroll to the cloud, businesses can significantly reduce the administrative burden while improving overall efficiency.

“Payroll processing providers today require reliable, efficient, and compliant payroll solutions. We help providers stay ahead by leveraging cloud platforms and automation to enhance operations and boost accuracy,” said Ajay Mehta, CEO. “Our focus is on providing businesses with the tools they need to manage payroll effectively while ensuring full compliance with ever-changing tax regulations.”

Automation is playing a pivotal role in reshaping payroll processing, as businesses increasingly turn to automated tools to streamline tasks such as calculating wages, tax deductions, and other essential functions. This shift significantly reduces the risk of human error and enhances efficiency. These automated systems also help businesses stay compliant with federal, state, and local tax regulations by providing real-time updates that reflect any changes in tax laws. By facilitating real-time payroll processing, businesses can manage their payroll obligations more effectively, ensuring smooth operations and minimizing the risk of compliance issues and delays.

As tax regulations continue to grow in complexity, many businesses are seeking expert guidance from payroll providers to navigate the intricacies of compliance. The frequent updates and varying regulations across states can make tax laws overwhelming to manage internally. Payroll service providers alleviate this burden by taking on the responsibility of ensuring businesses comply with all relevant tax rules, reducing the risk of costly fines and penalties. By outsourcing payroll functions, companies gain peace of mind, knowing their tax filings and related obligations are in the hands of professionals. This combination of automation and expertise not only enhances operational efficiency but also ensures businesses remain compliant in an ever-evolving regulatory landscape.

“With tax regulations constantly evolving, businesses must rely on innovative solutions to stay compliant and efficient. ‘Our goal is to provide payroll providers with advanced technology to address these challenges effectively,’ stated Ajay Mehta, CEO.”

In response to these needs, many payroll processing providers are integrating tax filing services into their offerings. By combining payroll processing with tax filing, businesses can streamline their financial operations. These integrated solutions automatically submit payroll taxes to the appropriate authorities, ensuring that businesses meet deadlines and avoid late fees. The ability to combine these services with a single platform offers significant time savings and ensures that businesses are fully compliant with tax laws.

Simplify your finances now—schedule your free 30-min consultation!

https://www.ibntech.com/free-consultation/?pr=ABnewswire

For small and medium-sized businesses (SMBs), managing payroll can be a challenging and time-consuming task. Outsourcing payroll processing allows SMBs to focus on growth and operational efficiency, leaving the complex work of payroll and tax management to the experts. Many payroll service providers offer scalable solutions that can grow with a business, making it easier for SMBs to access high-quality payroll services without the need to hire in-house payroll teams. These services offer the flexibility and expertise that SMBs need to ensure compliance and improve financial management.

The growing complexity of tax regulations and the need for operational efficiency have solidified the role of payroll processing providers as essential resources for U.S. businesses. By leveraging cloud-based platforms, automated tools, and integrated tax filing services, these providers are helping companies navigate the complexities of payroll management while ensuring compliance with ever-changing tax laws. As industry continues to evolve, payroll providers will remain a critical partner for businesses of all sizes, delivering the expertise and solutions necessary to meet the demands of modern payroll processing.

Curious about pricing? Contact us for a customized payroll quote!

https://www.ibntech.com/pricing/?pr=ABnewswire

As payroll processing evolves, providers across the U.S. are turning to advanced technologies to stay competitive. Companies like IBN Technologies are at the forefront, offering innovative solutions that integrate technology with payroll management systems. IBN Technologies enhances payroll service efficiency, reduces errors, and ensures compliance with evolving regulations through cloud platforms, automation tools, and real-time data updates.

The collaboration between payroll providers and technology leaders like IBN Technologies is proving crucial for U.S. businesses. By delivering scalable, customized solutions, IBN Technologies is empowering payroll service providers to meet the growing demands of their clients. As businesses seek to improve efficiency and ensure compliance, IBN Technologies’ forward-thinking solutions are driving significant improvements in the payroll processing sector. The role of technology-driven solutions will remain essential in helping businesses navigate the complexities of payroll management.

 

About IBN Technologies                    

IBN Technologies LLC, an outsourcing specialist with 25 years of experience, serves clients across the United States, United Kingdom, Middle East, and India. Renowned for its expertise in RPA, Intelligent process automation includes AP Automation services like P2P, Q2C, and Record-to-Report. IBN Technologies provides solutions compliant with ISO 9001:2015, 27001:2022, CMMI-5, and GDPR standards. The company has established itself as a leading provider of IT, KPO, and BPO outsourcing services in finance and accounting, including CPAs, hedge funds, alternative investments, banking, travel, human resources, and retail industries. It offers customized solutions that drive efficiency and growth.     

      

Media Contact
Company Name: IBN Technologies LLC
Contact Person: Pradip
Email: Send Email
Phone: +1 844-644-8440
Address:66, West Flagler Street Suite 900 Miami, FL, USA 33130
City: Miami
State: Florida
Country: United States
Website: https://www.ibntech.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Surging Demand for Payroll Processing Providers Amid Growing Tax Compliance Challenges

Healthcare Customer Relationship Management (CRM) Market Projected 47.60 USD Billion at a Thriving CAGR of 10.60% By 2034

“Healthcare Customer Relationship Management (CRM) Market”
Healthcare CRM Market Growth Research and Competitive Report Information By Type (Operational CRM, Analytical CRM, and Collaborative CRM), By Component (Software and Service), By Mode of Delivery (Cloud-Based, and On-Premise), By End-User (Communication Module, Patient Management, Task Management, and Report Module) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2034

The Healthcare Customer Relationship Management (CRM) Market is undergoing rapid expansion as healthcare providers increasingly adopt innovative technologies to enhance patient engagement, optimize operational workflows, and improve overall patient care. The integration of cutting-edge solutions such as Artificial Intelligence (AI), cloud computing, and big data analytics has significantly transformed the healthcare sector, making CRM systems essential. This report provides a comprehensive analysis of the Healthcare CRM market, detailing market size, key drivers, challenges, segmentation, regional trends, and emerging developments.

The Healthcare CRM Market Industry is expected to grow from 19.22 (USD Billion) in 2025 to 47.60 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 10.60% during the forecast period (2025 – 2034).

Healthcare Customer Relationship Management (CRM) Market Overview

The Healthcare CRM market is experiencing substantial growth as healthcare organizations recognize the need for effective patient management solutions. Market projections indicate continuous expansion, driven by technological advancements and the increasing focus on patient-centric care.

Key players in this market include,

Sugar CRM (US)

SAP SE (Germany)

Keona Health (US)

Microsoft (US)

Infor Inc. (US)

Healthgrades (US)

Oracle (US)

Influence Health (US)

Accenture (Ireland)

Sample Copy of the Report @

https://www.marketresearchfuture.com/sample_request/7324

The Healthcare CRM market is evolving rapidly, driven by the need for efficient patient management solutions, regulatory compliance, and technological advancements. As healthcare organizations continue to invest in CRM systems, emerging trends such as AI, cloud computing, and mobile applications will shape the future of the market. The increasing integration of predictive analytics, IoT, and blockchain technology is expected to further enhance the functionality and security of Healthcare CRM platforms. The market will continue to expand, addressing key challenges while providing innovative solutions to optimize patient care and operational efficiency.

Key Drivers of the Healthcare CRM Market

  1. Rising Demand for Patient-Centric Care: The shift toward personalized and patient-centered care models is a significant driver for CRM adoption. Healthcare providers leverage CRM systems to streamline communication, track patient interactions, and improve patient satisfaction.
  2. Technological Advancements: AI and machine learning integration in CRM solutions enable predictive analytics, automation of administrative tasks, and improved patient outcome predictions. These capabilities enhance the efficiency of healthcare operations.
  3. Growing Adoption of Telehealth: The rapid expansion of telehealth services necessitates CRM solutions to efficiently manage virtual patient interactions. CRM platforms support scheduling, communication, and follow-ups, ensuring seamless remote care.
  4. Regulatory Compliance and Data Management: Compliance with regulations such as HIPAA requires advanced CRM systems to ensure data security and proper handling of sensitive patient information. Secure CRM solutions help healthcare organizations manage and store patient data effectively.

Healthcare CRM Market Segmentation

The Healthcare CRM market is segmented into various categories based on type, components, mode of delivery, and end-users.

In terms of type, Healthcare CRM is classified into Operational CRM, Analytical CRM, and Collaborative CRM. Operational CRM focuses on streamlining daily healthcare operations, while Analytical CRM helps in data-driven decision-making. Collaborative CRM enhances communication and coordination among healthcare providers, improving patient care.

Regarding components, Healthcare CRM consists of Software and Services. The software component includes platforms and applications that facilitate patient relationship management, while services encompass consulting, implementation, and support.

The mode of delivery for Healthcare CRM solutions is categorized into Cloud-Based and On-Premise models. Cloud-Based CRM offers scalability, remote accessibility, and cost efficiency, whereas On-Premise solutions provide greater control and security for healthcare organizations.

Lastly, Healthcare CRM serves various end-users, including Hospitals & Clinics, Diagnostic Centers, Imaging Centers, and Research Institutes. Hospitals and clinics utilize CRM systems to enhance patient engagement and streamline operations. Diagnostic and imaging centers benefit from CRM solutions by managing patient data efficiently. Research institutes leverage CRM for data analysis and collaboration.

Overall, Healthcare CRM plays a crucial role in improving patient care, optimizing healthcare processes, and enhancing communication among stakeholders.

Challenges and Restraints

Data Security Concerns:

The handling of sensitive patient information raises concerns about cybersecurity threats and data breaches. Healthcare organizations must implement stringent security measures to protect patient data.

High Implementation Costs:

The initial investment and ongoing maintenance of CRM systems can be expensive, particularly for small and medium-sized healthcare providers.

Organizations must balance cost-effectiveness with the need for advanced CRM functionalities.

Integration Complexity:

Integrating CRM solutions with existing healthcare systems, such as electronic health records (EHRs), can be complex and time-consuming.

Interoperability issues may hinder seamless data exchange between platforms.

You Can Purchase Complete Report @

https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=7324

Emerging Trends in the Healthcare CRM Market

AI-Powered CRM Solutions:

AI-driven analytics and chatbots enhance patient engagement by automating interactions and providing real-time assistance.

Predictive analytics helps identify high-risk patients, allowing healthcare providers to implement proactive care strategies.

Cloud-Based CRM Systems:

The adoption of cloud technology enables scalability, flexibility, and cost-efficiency for healthcare providers.

Cloud-based CRM platforms facilitate remote access to patient data, improving care coordination.

Mobile CRM and Patient Apps:

The proliferation of mobile health applications allows patients to manage appointments, access medical records, and receive timely health updates.

Mobile CRM solutions enhance patient engagement and communication with healthcare providers.

Predictive Analytics for Patient Insights:

Advanced CRM systems leverage predictive analytics to assess patient health trends and personalize treatment plans.

Data-driven insights help healthcare providers allocate resources effectively and improve patient outcomes.

Integration with IoT and Wearable Devices:

The increasing use of wearable health devices generates real-time patient data, enabling better monitoring and decision-making.

CRM platforms integrate with IoT-enabled devices to enhance remote patient management.

Blockchain for Enhanced Security:

Blockchain technology is being explored to improve data security, ensure transparency, and enhance patient record management.

Decentralized data storage reduces the risk of data manipulation and unauthorized access.

 

Media Contact
Company Name: Market Research Future
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.marketresearchfuture.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Healthcare Customer Relationship Management (CRM) Market Projected 47.60 USD Billion at a Thriving CAGR of 10.60% By 2034

Coronary Artery Disease Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Coronary Artery Disease Pipeline Insight” report provides comprehensive insights about 30+ companies and 25+ pipeline drugs in Coronary Artery Disease pipeline landscape. It covers the Coronary Artery Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Coronary Artery Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Coronary Artery Disease Pipeline Report to explore emerging therapies, key Coronary Artery Disease Companies, and future Coronary Artery Disease treatment landscapes @ Coronary Artery Disease Pipeline Outlook Report

Key Takeaways from the Coronary Artery Disease Pipeline Report

  • In February 2025:- MedTrace Pharma A/S:- This a Phase 3, prospective, open-label, multicenter study of [15-O]-H2O injection for PET imaging of subjects with suspected CAD. Approximately 182 evaluable participants with suspected CAD referred for testing will be included in the study at approximately 10 study sites in the United States and Europe. Approximately 215 participants will be enrolled to account for an estimated 15% drop-out rate.
  • In February 2025:- Novartis Pharmaceuticals:- The purpose of this study is to evaluate the efficacy of inclisiran compared to placebo on top of maximally tolerated dose of statin therapy in reducing total coronary atheroma volume assessed by CCTA in participants with a diagnosis of Non-Obstructive Coronary Artery Disease (NOCAD) without previous cardiovascular events, who have an LDL-C ≥55 mg/dL (1.4 mmol//L), no significant pressure drop in Fractional Flow Reserve Computed Tomography (FFRCT) and a CT-adapted Leaman score >5 despite the use of maximally tolerated statin therapy(and if applicable, another LLT on top of statin therapy for at least 30 days in up to 20% of randomized participants).
  • In February 2025:- Beijing Inno Medicine Co., Ltd.:- This study is to evaluate the efficacy and safety of intravenously administered YN001 in patients with coronary atherosclerosis in Australia. This study will be conducted in eligible participants with a diagnosis of coronary atherosclerosis, and at least 1 coronary artery is blocked determined by coronary computed tomography angiography (CCTA)
  • DelveInsight’s Coronary Artery Disease pipeline report depicts a robust space with 30+ active players working to develop 25+ pipeline therapies for Coronary Artery Disease treatment.
  • The leading Coronary Artery Disease Companies such as Novartis Pharmaceuticals, Amgen, Imbria Pharmaceuticals, Inc., AstraZeneca, Jiangsu Vcare Pharmatech, GE Healthcare, and others.
  • Promising Coronary Artery Disease Therapies such as Rosuvastatin, Atorvastatin, Hexadecasaccharide (SR123781A), Rosuvastatin, Rimonabant (SR141716), Rosuvastatin calcium, and others.

Discover how the Coronary Artery Disease treatment paradigm is evolving. Access DelveInsight’s in-depth Coronary Artery Disease Pipeline Analysis for a closer look at promising breakthroughs @ Coronary Artery Disease Clinical Trials and Studies

Coronary Artery Disease Emerging Drugs

  • Flurpiridaz F-18: GE Healthcare

Flurpiridaz F-18, a fluorine 18-labeled agent was developed by Lantheus Medical Imaging for the diagnosis of coronary artery disease (CAD), the most common form of heart disease. Flurpiridaz F 18 is an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent. GE Healthcare has launched a second Phase III clinical trial for the use of Flurpiridaz 18F Injection in PET myocardial perfusion imaging (MPI) to detect CAD. Currently, it is in Phase III stage of clinical trial evaluation to treat Coronary Artery Disease.

  • Evolocumab: Amgen

Evolocumab injection is used to reduce the risk of a stroke or heart attack or the need for coronary artery bypass (CABG) surgery in people with cardiovascular disease. Evolocumab injection is also used along with diet alone or in combination with other cholesterol-lowering medications such as HMG-CoA reductase inhibitors (statins) or ezetimbe (Zetia) to decrease the amount of low-density lipoprotein (LDL) cholesterol (‘bad cholesterol’) in the blood, including people who have familial heterozygous hypercholesterolemia. It is also used along with diet changes and other treatments to reduce the amount low-density lipoprotein (LDL) cholesterol in the blood in people that have homozygous familial hypercholesterolemia. It is in a class of medications called proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor monoclonal antibody. It works by blocking the production of LDL cholesterol in the body to decrease the amount of cholesterol that may build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body. Currently, it is in Phase III stage of clinical trial evaluation to treat Coronary Artery Disease.

  • Revacept: advanceCor

Revacept seals the lesion in a blood vessel like a plaster. It acts locally at the ruptured plaque instead of involving the complete organism, as is the case for all established drugs. Revacept has proven to be very effective in laboratory tests with platelets and in animal experiments. In a Phase I clinical trial with volunteers, it was shown to be very well tolerated at all dosages. It induced a specific and dose-dependent inhibition of aggregation (clumping of platelets) in the blood of the volunteers without any relevant side effects. In particular, general haemostasis was not affected: The bleeding time was not prolonged by Revacept and there were no bleeding complications and no reduction in platelet count (thrombopenia). Currently, it is in Phase II stage of clinical trial evaluation to treat Coronary Artery Disease.

The Coronary Artery Disease pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Coronary Artery Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Coronary Artery Disease Treatment.
  • Coronary Artery Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Coronary Artery Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Coronary Artery Disease market.

Get a detailed analysis of the latest innovations in the Coronary Artery Disease pipeline. Explore DelveInsight’s expert-driven report today! @ Coronary Artery Disease Unmet Needs

Coronary Artery Disease Companies

Novartis Pharmaceuticals, Amgen, Imbria Pharmaceuticals, Inc., AstraZeneca, Jiangsu Vcare Pharmatech, GE Healthcare, and others.

Coronary Artery Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

Coronary Artery Disease Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Coronary Artery Disease Therapies and key Coronary Artery Disease Developments @ Coronary Artery Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Coronary Artery Disease Pipeline Report

  • Coverage- Global
  • Coronary Artery Disease Companies- Novartis Pharmaceuticals, Amgen, Imbria Pharmaceuticals, Inc., AstraZeneca, Jiangsu Vcare Pharmatech, GE Healthcare, and others.
  • Coronary Artery Disease Therapies- Rosuvastatin, Atorvastatin, Hexadecasaccharide (SR123781A), Rosuvastatin, Rimonabant (SR141716), Rosuvastatin calcium, and others.
  • Coronary Artery Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Coronary Artery Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Coronary Artery Disease drug development? Find out in DelveInsight’s exclusive Coronary Artery Disease Pipeline Report—access it now! @ Coronary Artery Disease Emerging Drugs and Major Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Coronary Artery Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Coronary Artery Disease – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Evolocumab: Amgen
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Ninerafaxstat: Imbria Pharmaceuticals, Inc.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Coronary Artery Disease Key Companies
  17. Coronary Artery Disease Key Products
  18. Coronary Artery Disease- Unmet Needs
  19. Coronary Artery Disease- Market Drivers and Barriers
  20. Coronary Artery Disease- Future Perspectives and Conclusion
  21. Coronary Artery Disease Analyst Views
  22. Coronary Artery Disease Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Coronary Artery Disease Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Animal Disinfectants Market Set to Soar: $5.31 Billion Worth Market by 2030 – Arizton

“Global Animal Disinfectants Market Research Report by Arizton”

According to Arizton’s latest research report, the global animal disinfectants market is growing at a CAGR of 6.22% during 2024-2030.

       

Looking for More Information? Click: https://www.focusreports.store/report/animal-disinfectants-market-focused-insights

 

Report Scope:       

Market Size (2030): $5.31 Billion 

Market Size (2024): $3.69 Billion 

CAGR (2024-2030): 6.22% 

Historic Year: 2021-2023 

Base Year: 2024 

Forecast Year: 2025-2030 

Market Segmentation: Product, Form, Application, Distribution Channel, and Geography

Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa 

 

Market Overview

The global animal disinfectants market is experiencing significant growth, driven by technological advancements, the development of eco-friendly and biodegradable solutions, and increasing demand for poultry disinfectants, alongside factors like the growth of animal care centers, intensified animal farming, and rising infectious diseases. Consumer preferences are shifting towards sustainable options, and regular disinfection in poultry farming is essential to prevent disease transmission. Specialized disinfectants are in high demand from veterinary clinics, while general products are widely available in pharmacies and agricultural settings. Major market players include DeLaval Inc, Ecolab, and Zoetis, with ongoing innovations like electrostatic spraying and nanotechnology improving disinfectant efficacy. China dominates the APAC region, fueled by growing biosecurity awareness and its large livestock industry.

 

Expansion of Animal Care Centers Boosting Revenue in the Animal Disinfectants Market

The growth in animal care centers is a significant trend in the global animal disinfectants market, contributing to its increasing revenue. This expansion is driven by several factors, including the premiumization of animal care, the humanization of animals, heightened awareness of zoonotic diseases, growth in veterinary services, innovations in disinfectant care, and a greater focus on preventive health measures. Rising disposable incomes, lifestyle changes, and urbanization have led to a global increase in animal ownership, fueling demand for hygiene products such as animal disinfectants. As pet owners become more conscious of maintaining the health and hygiene of their animals, there is greater investment in disinfecting grooming spaces, veterinary clinics, and living areas. With growing concerns over zoonotic diseases, both professionals and pet owners are prioritizing disinfectants to reduce health risks.

 

Additionally, stringent regulations from industry bodies and governments regarding hygiene standards for animal care facilities have encouraged the use of high-quality disinfectants. In the U.S., the number of animal shelters is increasing, with around 3,500 shelters and 6.3 million animals entering them annually, according to the American Society for the Prevention of Cruelty to Animals (ASPCA). The rise of veterinary hospitals and clinics has further increased the use of disinfectants to maintain sterile environments. Overall, the regular use of animal disinfectants is becoming an essential component of preventive healthcare for animals, driving market growth and boosting revenue by minimizing the risks of diseases and infections.

 

Recent Vendor Activities

  • In 2024, the leading animal disinfectant company, DeLaval Inc. launched its product Titan. It is a pioneering barrier teat disinfectant for automated spray systems. It’s one of the best developments for the dairy application and one of the first of its kind on the market. Titan represents a significant advancement in udder health management. Its innovative film-forming technology creates a barrier film on the teats, helping to protect against environmental pathogens like S. uberis and E. coli – prevalent causes of mastitis.
  • In 2024, a food and animal safety solution company, Neogen Corporation launched Farm Fluid MAX disinfectant in the UK poultry and livestock market. In the coming years, it will be available in other European markets. This dual-action disinfectant is designed for challenging farm conditions and is formulated for use as part of a Neogen Pathogen Program.

 

The Role of Offline Sales Channels in the Animal Disinfectants Market

The offline segment of the animal disinfectants market includes direct sales by manufacturers, retail stores, agricultural supply stores, veterinary pharmacies, and more. Veterinary clinics and hospitals often play a significant role by recommending and selling disinfectants directly to animal owners, offering expert guidance on product usage and specifications. Many pet owners trust their vets’ advice when selecting disinfectants. Livestock producers and farmers typically purchase disinfectants in bulk from agricultural supply stores, benefiting from discounted prices on large quantities and strong relationships built between vendors and buyers. Drugstores and pharmacies, though convenient for smaller needs, contribute less to the market due to their limited selection of specialized disinfectants. While the demand for specialized disinfectants continues to rise in veterinary clinics, general animal disinfectants are more readily available in pharmacies and agricultural outlets. Although online sales channels are expanding, offline stores will continue to be crucial in the animal disinfectants market, especially for personalized advice and bulk purchases.

 

China’s Dominance in the APAC Animal Disinfectants Market

China holds a dominant market share in the APAC animal disinfectants market, driven by factors such as increased awareness of biosecurity and animal health, along with its massive livestock industry. As the world’s largest producer of poultry, eggs, and pork, China has a significant demand for animal disinfectants to prevent disease spread and manage outbreaks. In 2020, China had over 5.7 billion poultry, and by 2021, its population consumed around 57 million tons of pork, creating a substantial need for disinfectants to support intensive farming operations. Disease outbreaks, like Avian Influenza and African Swine Fever (ASF), have highlighted the importance of effective disinfection practices. The Chinese government is committed to animal health and food safety, implementing strict regulations regarding animal disinfectants in livestock production. The market is competitive, with both global and domestic disinfectant brands available, offering products such as iodophors, aldehydes, phenols, and quaternary ammonium compounds. Additionally, there is growing demand for sustainable and biodegradable disinfectant options, which is expected to drive further market growth in China during the forecast period.

 

Looking for More Information? Click: https://www.focusreports.store/report/animal-disinfectants-market-focused-insights

 

Segmentation & Forecasts

 

Product

  • Iodine
  • Lactic Acid
  • Hydrogen Peroxide
  • Others

 

Form

  • Liquid
  • Powder
  • Others

 

Application

  • Dairy & Ruminants
  • Poultry
  • Swine
  • Aquaculture
  • Equine

 

Distribution Channel

  • Offline
  • Online

 

Geography

 

North America

  • The US
  • Canada

 

Europe

  • Germany
  • France
  • The UK
  • Italy
  • Spain

 

APAC

  • China
  • Japan
  • South Korea
  • Australia
  • India

 

Latin America

  • Brazil
  • Mexico

 

Middle East & Africa

  • Turkey
  • South Africa
  • Saudi Arabia

 

Vendor Lists

  • DeLaval Inc
  • Ecolab
  • Evans Vanodine International PLC
  • Evonik Industries AG
  • GEA Group
  • KERSIA GROUP
  • LANXESS
  • Neogen Corporation
  • Solvay
  • Zoetis Services LLC
  • AdvaCare Pharma
  • Albert Kerbl GmbH
  • Bona AB
  • Elanco Animal Health Incorporated
  • FINK TEC GmbH
  • G Shepherd Animal Health
  • Kemin Industries, Inc.
  • Laboratoires CEETAL
  • PCC Group
  • Planet Pets
  • Sanosil AG
  • Solenis International LLC
  • Stepan Company
  • Steroplast Healthcare Limited
  • STOCKMEIER Group
  • Sunways Bioscience LLP
  • Thymox
  • Veesure
  • Vetoquinol
  • Virbac
  • Virox

      

What Key Findings Will Our Research Analysis Reveal?     

How big is the global animal disinfectants market?

Which region holds the largest share of the global animal disinfectants market?

Who are the major players in the global animal disinfectants market?

         

Why Arizton?                                                

100% Customer Satisfaction                                                

24×7 availability – we are always there when you need us                                                

200+ Fortune 500 Companies trust Arizton’s report                                                

80% of our reports are exclusive and first in the industry                                                

100% more data and analysis                                                

1500+ reports published till date                              

                   

Post-Purchase Benefit                                            

  • 1hr of free analyst discussion                                            
  • 10% off on customization                         

                  

About Us:                                                                                     

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts. 

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.    

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.focusreports.store/report/animal-disinfectants-market-focused-insights

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Animal Disinfectants Market Set to Soar: $5.31 Billion Worth Market by 2030 – Arizton

Bio-based Leather Market Size, Growth Rate, Industry opportunities with Top Key Players and Expert Review by 2028

“Browse 250 market data Tables and 40 Figures spread through 236 Pages and in-depth TOC on “Bio-based Leather Market””
The bio-based leather market is gaining traction as sustainability drives demand for eco-friendly alternatives to traditional leather. Innovations in plant-based and lab-grown materials are fueling growth, with the fashion and automotive industries leading adoption. As regulations tighten, bio-based leather is set to expand, offering a greener future.

In terms of value, the bio-based leather market is estimated to grow from USD 107 million in 2023 to USD 216 million by 2028, at a CAGR of 15.0%. The market research report is a comprehensive analysis of the bio-based leather market trends, future prospects, and other pivotal factors that drive the market. Rising demand for eco-friendly and sustainable leather materials from industries such as footwear, garments & accessories, furniture, and automotive for a variety of applications is leading the market. In addition, most of the key industry players are investing in heavy research and development for more durable materials. During the forecast period, this is anticipated to expand the bio-based leather market even more. In contrast, the market growth is being constrained by expensive product costs & R&D expenses and the durability of bio-based leather.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=206086810

“Mushroom was the largest source for bio-based leather market in 2022 in terms of value.”

The bio-based leather market is experiencing significant growth driven by several key factors. Mushrooms, specifically mycelium, have attracted attention as a prospective source in the bio-based leather market for various reasons. Mycelium leather can be manufactured to have specific features such as texture, thickness, and durability, making it versatile and appropriate for a wide range of applications such as fashion, accessories, and furniture. Biotechnology and material science advancements have improved the manufacturing method and quality of mushroom-based leather, making it a more viable choice for the fashion and textile industries.

“Garments & accessories segment is estimated to be the largest end-use industry in bio-based leather market between 2023 and 2028 in terms of value.”

The bio-based leather market has been gradually expanding, with increased investment and research in producing better materials and manufacturing methods. Clothing and accessories, such as shoes, handbags, belts, and wallets, are high-fashion consumer items. People seek apparel and accessories that are not only functional but also fashionable and trendy. Bio-based leather is a sustainable and ethical solution that meets the growing demand for cruelty-free and eco-friendly design. The texture, appearance, and feel of bio-based leather can be created to closely resemble that of animal leather. This makes it a popular alternative for fashion designers and brands looking to build items that meet consumers’ quality and aesthetic requirements.

“Europe was the largest region for the bio-basd leather market in 2022, in terms of value.”

The expansion of the bio-based leather market in the Europe region is primarily due to strict regulations regarding animal leather and the product sustainability. The Europe area has a sizable consumer market, making it an appealing destination for bio-based leather manufacturers and investors. On the other hand, Asia Pacific is estimated to be the fastest growing region in this market. Many Asia Pacific countries, particularly China and India, have expressed a desire to promote green and sustainable industries. Notably, most of this growth in the Asia Pacific region is anticipated to be concentrated in key countries such as India, China, South Korea, Japan, and various Southeast Asian nations.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=206086810

Bio-Based Leather Companies

The key players in this market are Natural Fiber Welding, Inc. (US), Ananas Anam Ltd. (UK), MycoWorks Inc. (US), Bolt Threads Inc. (US), Modern Meadows (US), Adriano di Marti (Mexico), Ultrafabrics Holdings Co., Ltd. (US), Beyond Leather Materials (Denmark), Fruitleather Rotterdam (Netherlands), and VEGEA (Italy). These companies are known for developing a wide variety of bio-based leather used in various end-use industries. To address the rising demand for bio-based leather across a range of applications, players in the bio-based leather market are primarily focusing on their research and development. Companies may improve their source range and better quality of leather to promote bio-based leather.

The new product launches between 2019 and 2023 have had a substantial influence on the expansion of the bio-based leather market. Different businesses have used various approaches to strengthen their positions in the bio-based leather market. For instance, Natural Fiber Welding, Inc., MycoWorks Inc., Bolt Threads Inc., Modern Meadows, Adriano di Marti, and Ultrafabrics Holdings Co., Ltd. primarily focus on the North American and South American regions, whereas Ananas Anam Ltd., Beyond Leather Materials, Fruitleather Rotterdam, and VEGEA has a major concentration on the European region. In essence, these businesses have solidified their presence in their home regions and are looking for ways to diversify geographically to grow their company operations. Additionally, during the past few years, all these companies have been committed to strengthening their product portfolios and market presence through strategic alliances.

Natural Fiber Welding, Inc. is a precursor in the field of biotechnology in the US. Natural Fiber Welding, Inc. has emerged as a pioneer in the development of sustainable materials. The core focus of the company is the research and commercialization of new, plant-based materials that are environmentally friendly, adaptable and have the potential to replace traditional materials in a variety of industries. Natural Fiber Welding, Inc.’s innovative method, “Mirum,” transforms natural fibers and agricultural leftovers into strong, durable, and customizable materials. For instance, in June 2023, the company announced a partnership with Ahima that will make it easier to develop footwear made with MIRUM. This partnership will help the company to cover a wide range of markets. Moreover, in February 2023, the company announced the partnership with Lenzing AG to offer TENCEL branded fibers as another backer option for Natural Fiber Welding, Inc. patented plant-based technology, MIRUM. The partnership will help the company to develop infinite possibilities for application from the new material.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=206086810

Ananas Anam Ltd. is a pioneering sustainable materials company known for its innovative creation, Pinatex. The company has revolutionized the fashion and textile industries with its plant-based, non-woven textile material made from pineapple leaf fibers. Pinatex is derived from the byproduct of pineapple cultivation, reducing agricultural waste. Ananas Anam Ltd. has garnered global recognition for its commitment to sustainability and ethical practices. The company collaborates with renowned brands and designers to incorporate Pinatex into their products, offering a cruelty-free and sustainable alternative to traditional leather and synthetic materials. For instance, in July 2021, the company entered a partnership with Dole Sunshine Company to access a larger volume of pineapple fibers to meet the increasing demand for Pinatex.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/bio-based-leather-market-206086810.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bio-based Leather Market Size, Growth Rate, Industry opportunities with Top Key Players and Expert Review by 2028

Queens Pedestrian Accident Lawyer Keetick L. Sanchez Highlights Legal Options for Injured Pedestrians

Queens pedestrian accident lawyer Keetick L. Sanchez (https://accidentlawyer-queens.com/queens-pedestrian-accident-lawyer/), of K L Sanchez Law Office, P.C., provides crucial legal guidance to individuals injured in pedestrian accidents, helping them manage the complex aspects of insurance claims and lawsuits. With the busy streets of Queens posing constant risks, victims often face serious injuries and financial uncertainty. Securing fair compensation can be challenging, as insurance companies frequently offer settlements that do not fully cover medical expenses, lost wages, and long-term recovery costs. Having legal representation can help injured pedestrians understand their rights and pursue the compensation they deserve.

Given the complexity of pedestrian accident cases, Queens pedestrian accident lawyer Keetick L. Sanchez emphasizes the importance of acting quickly. “Pedestrian accidents can lead to life-changing injuries, and victims need to be aware of their legal rights. Seeking legal assistance early helps ensure that critical evidence is preserved and that victims have the best chance at securing the compensation they need for their recovery,” says Sanchez.

Pedestrian accidents in Queens are often caused by factors such as distracted driving, speeding, and failure to yield at crosswalks. High-risk areas such as Queens Boulevard, also known as the “Boulevard of Death,” and Roosevelt Avenue, where foot traffic is heavy, see frequent pedestrian-related incidents. The Queens pedestrian accident lawyer also notes that poor visibility, left-turn collisions, and reckless driving further contribute to these accidents, increasing the likelihood of severe injuries.

A Queens pedestrian accident lawyer can help identify the cause of an accident and determine liability. Many accidents occur because drivers fail to follow traffic laws, but in some cases, pedestrians may also bear partial responsibility. New York’s comparative negligence rule allows victims to recover damages even if they were partially at fault, but their compensation is reduced by their percentage of responsibility.

Pedestrians injured in accidents may suffer from traumatic brain injuries, spinal cord damage, broken bones, and internal injuries. These injuries often require extensive medical treatment and long-term rehabilitation, adding to the financial burden of the victim and their family.

New York’s no-fault insurance system covers medical expenses and lost wages up to $50,000, but it does not compensate for pain and suffering. Victims who suffer serious injuries may file a lawsuit to seek additional damages. Keetick L. Sanchez stresses the importance of understanding these options, stating, “New York’s no-fault system provides initial relief, but for those with serious injuries, pursuing additional compensation through legal action may be necessary to cover long-term expenses and non-economic losses.”

A Queens pedestrian accident lawyer can also help victims explore other sources of compensation, such as the at-fault driver’s insurance, personal health insurance, and personal injury lawsuits. Cases involving hit-and-run accidents or uninsured drivers require a different legal approach, making experienced legal representation crucial.

Pedestrian accident victims in New York must adhere to strict filing deadlines to seek compensation. The statute of limitations for personal injury claims is generally three years from the date of the accident, while wrongful death claims must be filed within two years of the victim’s passing. Cases involving government entities, such as those caused by poorly maintained roads or malfunctioning traffic signals, require a notice of claim to be filed within 90 days of the incident.

Delaying legal action can weaken a case, as crucial evidence such as surveillance footage and witness testimony may become unavailable over time. Keetick L. Sanchez advises victims to seek legal counsel as soon as possible, helping ensure they meet all necessary deadlines and have a strong case.

Establishing liability in pedestrian accident cases is critical to securing compensation. While drivers are often at fault, pedestrians who fail to follow traffic laws or act recklessly may share some responsibility. Additionally, third-party liability may come into play in cases involving employers, vehicle owners, or government agencies responsible for hazardous road conditions.

Pedestrian accidents can lead to life-altering consequences, and the recovery process can be overwhelming. Keetick L. Sanchez and the team at K L Sanchez Law Office, P.C. are dedicated to protecting the rights of injured pedestrians by handling the legal process while victims focus on healing.

Taking legal action promptly allows victims to pursue the financial support they need to rebuild their lives. Keetick L. Sanchez urges accident victims to seek legal counsel immediately to explore their options and move forward with confidence.

About K L Sanchez Law Office, P.C.:

K L Sanchez Law Office, P.C. is a Queens-based law firm dedicated to representing victims of personal injury accidents, including pedestrian accidents, construction accidents, and motor vehicle collisions. Led by Keetick L. Sanchez, the firm is committed to fighting for the rights of injured individuals, helping ensure they receive fair compensation for their losses.

Embeds:

Youtube Video: https://www.youtube.com/watch?v=RrTgja3zqgM

GMB: https://www.google.com/maps?cid=2729652254808699760

Email and website

Email: accidentlawny1@gmail.com

Website: https://accidentlawyer-queens.com/

Media Contact
Company Name: K L Sanchez Law Office, P.C.
Contact Person: Keetick Sanchez
Email: Send Email
Phone: (646) 701-7990
Address:3763 83rd St #1m
City: Jackson Heights
State: New York 11372
Country: United States
Website: https://accidentlawyer-queens.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Queens Pedestrian Accident Lawyer Keetick L. Sanchez Highlights Legal Options for Injured Pedestrians

Talent Acquisition And Staffing Technology Market Expected to Reach USD 67.32 Billion with a 9.93% CAGR by 2034

“Talent Acquisition and Staffing Technology empowers organizations to find, engage, and hire top talent faster through innovation, automation, and data-driven insights”
Talent Acquisition and Staffing Technology streamlines recruitment processes through AI-driven automation, data analytics, and digital platforms to enhance hiring efficiency and candidate experience.

Talent Acquisition and Staffing Technology Market Overview

According to a new report published by Market Research Future (MRFR), Talent Acquisition and Staffing Technology Market is expected to expand from USD 28.71 billion in 2025 to USD 67.32 billion by 2034, reflecting a compound annual growth rate (CAGR) of 9.93% during the forecast period (2025–2034). Furthermore, the market was valued at USD 26.11 billion in 2024.

The Talent Acquisition and Staffing Technology Market is experiencing rapid growth as businesses worldwide seek advanced solutions to streamline their hiring processes and improve workforce management. With the increasing adoption of artificial intelligence (AI), machine learning (ML), and automation, organizations are leveraging innovative tools to enhance candidate sourcing, screening, interviewing, and onboarding. The demand for data-driven recruitment strategies, remote hiring solutions, and diversity and inclusion initiatives further fuels the expansion of this market. Additionally, the rise of the gig economy and freelance workforce has led to the need for adaptable and scalable hiring technologies that cater to both permanent and contingent staffing requirements.

Download Sample Report (Get Full Insights in PDF – 128 Pages) at: https://www.marketresearchfuture.com/sample_request/26520

Key Companies in the Talent Acquisition And Staffing Technology Market Include:

  • Avionté
  • Oracle
  • Greenhouse
  • Lumesse
  • Kronos Incorporated
  • iCIMS
  • Ceridian HCM
  • SAP
  • ADP
  • Bullhorn
  • iCIMS
  • IBM
  • Workday
  • PeopleFluent
  • LinkedIn

These organizations offer a range of AI-powered recruitment platforms, applicant tracking systems (ATS), and human resource management solutions that help businesses optimize their hiring processes. Emerging startups and niche players like iCIMS, SmartRecruiters, Jobvite, and HireVue are also gaining traction by providing specialized recruitment automation tools, AI-driven assessments, and video interviewing solutions. Additionally, major job boards and recruitment marketplaces like Indeed and Glassdoor continue to play a significant role in shaping the industry by offering innovative job-matching algorithms and employer branding solutions.

The Talent Acquisition and Staffing Technology Market can be segmented based on technology, application, organization size, industry vertical, and deployment mode. By technology, key segments include AI-powered recruitment tools, cloud-based applicant tracking systems, predictive analytics, and video interviewing platforms. In terms of application, the market is categorized into candidate sourcing, screening and assessment, interview management, onboarding, and workforce analytics. Organization size segmentation covers small and medium-sized enterprises (SMEs) and large enterprises, with different adoption levels based on budget constraints and hiring volumes. Industry verticals such as IT and telecom, healthcare, retail, BFSI, manufacturing, and education are key consumers of recruitment technology solutions. Deployment modes include on-premise and cloud-based solutions, with cloud adoption witnessing significant growth due to its scalability and cost-efficiency.

Buy Now Premium Research Report – https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=26520

Market dynamics are driven by several factors, including the increasing reliance on data-driven recruitment, the growing need for automation, and the shift towards remote hiring and virtual onboarding. Companies are prioritizing candidate experience and employer branding, leading to the development of personalized recruitment marketing strategies. The integration of AI and ML into recruitment processes enables recruiters to identify top talent more efficiently while reducing biases in hiring. However, challenges such as data privacy concerns, high implementation costs, and resistance to technological adoption among traditional HR teams can hinder market growth. Additionally, regulatory compliance related to hiring practices and labor laws poses complexities for multinational organizations investing in staffing technology solutions.

Recent developments in the Talent Acquisition and Staffing Technology Market highlight the ongoing evolution of recruitment technologies. AI-driven chatbots and virtual assistants are becoming mainstream, assisting recruiters in engaging with candidates and answering their queries in real time. Predictive analytics is gaining traction, allowing organizations to assess candidate potential based on historical hiring data and performance metrics. The rise of skills-based hiring has led to the development of assessment tools that evaluate candidates based on competencies rather than traditional resumes. Moreover, blockchain technology is being explored for secure and verifiable credential verification, reducing the risk of fraudulent qualifications. Companies are also focusing on enhancing diversity, equity, and inclusion (DEI) through bias-free AI recruitment solutions that ensure fair candidate selection processes.

Browse In-depth Market Research Report – https://www.marketresearchfuture.com/reports/talent-acquisition-staffing-technology-market-26520

Regionally, North America leads the Talent Acquisition and Staffing Technology Market due to the strong presence of technology providers and the early adoption of AI-powered hiring solutions. The United States, in particular, is at the forefront, with large enterprises investing heavily in recruitment automation to attract top talent in competitive industries like IT, finance, and healthcare. Europe follows closely, with countries such as the UK, Germany, and France emphasizing compliance-driven hiring solutions and diversity-focused recruitment strategies. The Asia-Pacific region is witnessing rapid growth, driven by digital transformation initiatives in emerging economies like India, China, and Japan. The increasing penetration of cloud-based HR solutions and mobile-first recruitment platforms further fuels market expansion in this region. Latin America and the Middle East & Africa are gradually adopting staffing technology, with a focus on improving workforce mobility and addressing skill gaps through digital hiring solutions.

In conclusion, the Talent Acquisition and Staffing Technology Market is poised for continuous growth, driven by advancements in AI, automation, and data analytics. As businesses increasingly prioritize efficiency, diversity, and candidate experience in recruitment, the demand for innovative hiring solutions is expected to surge. While challenges such as regulatory compliance and data privacy persist, ongoing technological innovations and strategic collaborations among market players will shape the future of recruitment technology. Organizations that embrace digital hiring trends and invest in next-generation staffing solutions will gain a competitive edge in attracting and retaining top talent in the evolving job market.

Explore MRFR’s Related Ongoing Coverage In ICT Domain:

B2B SaaS Market – https://www.marketresearchfuture.com/reports/b2b-saas-market-42826

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Media Contact
Company Name: Market Research Future
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.marketresearchfuture.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Talent Acquisition And Staffing Technology Market Expected to Reach USD 67.32 Billion with a 9.93% CAGR by 2034

Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Marginal Zone Lymphoma Pipeline Insight” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Marginal Zone Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Marginal Zone Lymphoma Pipeline Report to explore emerging therapies, key Marginal Zone Lymphoma Companies, and future Marginal Zone Lymphoma treatment landscapes @ Marginal Zone Lymphoma Pipeline Outlook Report

Key Takeaways from the Marginal Zone Lymphoma Pipeline Report

  • In February 2025:- BeiGene:- The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
  • In February 2025:- Regeneron Pharmaceuticals:- This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called “relapsed”), or did not respond to treatment (called “refractory”). FL and MZL are subtypes of Non-Hodgkin ‘s lymphoma (NHL).
  • In February 2025:- Oncternal Therapeutics Inc.:- This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has been shown to play a role in cell signaling that cause leukemia and lymphoma cells to grow and survive. ROR1 is rarely found on healthy cells.
  • In February 2025:- Genmab:- The purpose of the dose-escalation part of the trial is to determine the maximum tolerated dose (MTD) and the recommended Phase-2 dose (RP2D), as well as to establish the safety profile of epcoritamab in Japanese patients with relapsed, progressive or refractory B-cell lymphoma and Japanese patients with B-cell lymphomas that have achieved partial response (PR) or complete response (CR).
  • In February 2025:- Janssen Research & Development LLC:- The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in adult participants with previously treated indolent Non-Hodgkin lymphoma.
  • DelveInsight’s Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Marginal Zone Lymphoma treatment.
  • The leading Marginal Zone Lymphoma Companies such as Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
  • Promising Marginal Zone Lymphoma Therapies such as Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others.

Discover how the Marginal Zone Lymphoma treatment paradigm is evolving. Access DelveInsight’s in-depth Marginal Zone Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Marginal Zone Lymphoma Clinical Trials and Studies

Marginal Zone Lymphoma Emerging Drugs

  • Tafasitamab: Incyte Corporation

Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. The therapy is currently in Phase III stage of clinical trial evaluation to treat Marginal Zone Lymphoma.

  • Amdizalisib (HMPL-689): HUTCHMED

The investigational drug candidate amdizalisib is a novel, selective small molecule inhibitor targeting the isoform phosphoinositide 3’-kinase delta (PI3Kδ), a key component in the B-cell receptor signaling pathway. We have designed amdizalisib with increased PI3Kδ isoform selectivity. Amdizalisib’s pharmacokinetic properties have been found to be favorable with good oral absorption, moderate tissue distribution and low clearance in pre-clinical pharmacokinetic studies. Amdizalisib is being investigated in studies in the U.S., Europe, China and Australia in various subtypes of advanced relapsed or refractory non-Hodgkin’s lymphoma, including follicular lymphoma and marginal zone lymphoma.

  • Orelabrutinib: InnoCare Pharma

Orelabrutinib is a small molecule Bruton’s tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases. In the field of oncology, InnoCare received approval for orelabrutinib from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lymphoma (R/R SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (R/R MCL). Currently, it is in Phase II stage of clinical trial evaluation to treat Marginal Zone Lymphoma (MZL).

  • EO2463: Enterome

EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine that combines four microbiome-peptides of B lymphocyte-specific lineage markers. EO2463 is designed to trigger the immune system into recognizing B cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes that cause NHL.

The Marginal Zone Lymphoma pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Marginal Zone Lymphoma Treatment.
  • Marginal Zone Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Marginal Zone Lymphoma market.

Get a detailed analysis of the latest innovations in the Marginal Zone Lymphoma pipeline. Explore DelveInsight’s expert-driven report today! @ Marginal Zone Lymphoma Unmet Needs

Marginal Zone Lymphoma Companies

Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.

Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

Marginal Zone Lymphoma Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

Download DelveInsight’s latest report to gain strategic insights into upcoming Marginal Zone Lymphoma Therapies and key Marginal Zone Lymphoma Developments @ Marginal Zone Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Marginal Zone Lymphoma Pipeline Report

  • Coverage- Global
  • Marginal Zone Lymphoma Companies-Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
  • Marginal Zone Lymphoma Therapies- Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others.
  • Marginal Zone Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Marginal Zone Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Marginal Zone Lymphoma drug development? Find out in DelveInsight’s exclusive Marginal Zone Lymphoma Pipeline Report—access it now! @ Marginal Zone Lymphoma Emerging Drugs and Major Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Marginal Zone Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Marginal Zone Lymphoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Tafasitamab: Incyte Corporation
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Orelabrutinib: InnoCare Pharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. EO2463: Enterome
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Marginal Zone Lymphoma Key Companies
  21. Marginal Zone Lymphoma Key Products
  22. Marginal Zone Lymphoma- Unmet Needs
  23. Marginal Zone Lymphoma- Market Drivers and Barriers
  24. Marginal Zone Lymphoma- Future Perspectives and Conclusion
  25. Marginal Zone Lymphoma Analyst Views
  26. Marginal Zone Lymphoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/knee-reconstruction-devices-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies